Company news

Avacta Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Results of Immunogenicity Study with Human Samples

April 3, 2017

Interim Results for the Period Ended 31 Jan 2017

April 3, 2017

Avacta Presents at Investor Evening Hosted by TPI

March 31, 2017

London Growth and Innovation Forum Presentation

March 31, 2017

Avacta to present at the UK Investor Show

March 22, 2017

Hardman Research: Low response would be positive!

March 21, 2017

Presenting at London Growth and Innovation Forum

January 11, 2017

Notice of AGM, Accounts and Directorate Change

December 1, 2016

Technical Update: Affinity Separation

November 23, 2016

Cancer Expert joins Scientific Advisory Board

November 7, 2016

CAR-T Cell Therapy Research Collaboration in US

November 2, 2016

Results from first Affimer pre-clinical studies

November 1, 2016

Director's Dealing

October 21, 2016

Hardman Research: Great strides to strategic goals

October 17, 2016

Prelim Results for the Year Ended 31 July 2016

October 17, 2016

Positive results from first preclinical studies

September 22, 2016

Change of Adviser

September 12, 2016

Change of Registered Office

August 31, 2016

New Facilities in Cambridge and Wetherby

August 16, 2016

Grant Funding

August 10, 2016

Key Affimer patents to be granted in Europe and US

August 3, 2016

Trading Statement

August 1, 2016

Hardman report: New Affimer opportunities

July 19, 2016

Collaboration with Glythera

July 14, 2016

Affimer Binders for Zika Virus Diagnostics

June 22, 2016

Collaboration with Mologic

June 13, 2016

Half-year Report

April 25, 2016

Affimer Therapeutic Platform Development Milestone

April 19, 2016

Investor Evening

April 5, 2016

Avacta Establishes Scientific Advisory Board

March 7, 2016

Grant Funding Awarded

February 24, 2016

Hardman & Co Issues Research Report

February 23, 2016

Directors' Dealings and Issue of Equity

February 17, 2016

Share Consolidation

January 26, 2016

Pre-close trading update

January 25, 2016

Philippe Cotrel Appointed Chief Commercial Officer

January 25, 2016

Proposed Shareholder Consolidation

January 21, 2016

Posting of Annual Report & Accounts and AGM Notice

January 7, 2016

Appointment of Tony Gardiner as CFO

December 10, 2015

Affimers improve disease resistance in plants

October 19, 2015

Robust performance of Affimers on Luminex platform

October 9, 2015

Appoints Dr Mike Owen as Non-executive Director

September 17, 2015

Total Voting Rights

September 10, 2015

Conditional Placing to Raise up to £22.0 Million

July 15, 2015

Pre-Close Trading Update

July 7, 2015

Re Agreement

May 18, 2015

Half Yearly Report

April 28, 2015

Drug discovery partnership

March 23, 2015

Sale of Optim Trade and Assets

February 12, 2015

Affimer Development Contract with Protatonce

February 9, 2015

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.